GlaxoSmithKline says $20 million SEC settlement ends US probes of China FCPA case
GlaxoSmithKline will pay the US Securities and Exchange Commission $20 million to settle allegations that it violated the books and records and internal controls provisions of the Foreign Corrupt Practices Act...To view the full article, register now.
Already a subscriber? Click here to view full article